Determining Effective Therapy for Mpox

This editorial addresses the urgent need for effective treatments for mpox, especially the clade I variant prevalent in central and eastern Africa. Highlighting the PALM007 randomized controlled trial, the article discusses the lack of significant efficacy of tecovirimat in reducing lesion resolution time or viral clearance. It explores pharmacokinetic concerns and inadequate drug concentrations, despite prior approvals based on animal models. The author emphasizes the necessity of rigorous human trials over expanded-access programs and advocates for further investigation into alternative agents like brincidofovir and monoclonal antibodies. The editorial concludes with a call for swift, coordinated clinical research to guide mpox treatment strategies and inform pandemic response preparedness.

This editorial addresses the urgent need for effective treatments for mpox, especially the clade I variant prevalent in central and eastern Africa. Highlighting the PALM007 randomized controlled trial, the article discusses the lack of significant efficacy of tecovirimat in reducing lesion resolution time or viral clearance. It explores pharmacokinetic concerns and inadequate drug concentrations, despite prior approvals based on animal models. The author emphasizes the necessity of rigorous human trials over expanded-access programs and advocates for further investigation into alternative agents like brincidofovir and monoclonal antibodies. The editorial concludes with a call for swift, coordinated clinical research to guide mpox treatment strategies and inform pandemic response preparedness.